David Lim

Managing Director, Raffles Venture Partners

David is co-founder and Managing Director of Raffles Venture Partners since 2008. David led the launch and management of funds that invest into top-tier US-led funds, as well as direct investment and co-investment into Singapore and overseas startups. Exits include Spinal Modulation Inc (acquired by St. Jude Medical), NFocus Neuromedical Inc (acquired by Covidien PLC) and Corous360 (acquired by DeClout SGX 5UZ.SI). David is currently a director or alternate on Asia Genomics Pte Ltd, Knorex Pte Ltd and Gnossem Pte Ltd.

Prior to Raffles Venture Partners, David was senior vice president of TIF Ventures, a wholly-owned investment company of Singapore EDBI. He was head of the US West Coast Fund-of-Funds and direct investment VISS Fund with exits that include Biosensors (SGX: BIOSEN), Savi (acquired by Lockheed Martin) and SoundBuzz (acquired by Motorola).

Prior to TIF Ventures, David was a senior management member of the National Science & Technology Board (now called A*STAR), where he was Director of New Business Division responsible for multiple technopreneurship programmes under the Government‘s US$1 billion Technopreneurship 21 (T21) initiative. His earlier responsibilities include funding of public sector R&D and national research institutions/centres; promotion and funding of private sector R&D.

Before NSTB, David was a lead R&D, manufacturing and reliability engineer in radio and electronic communication products with Motorola and Delco. David has a Master’s Degree in Management of Technology from the NUS’ Business School and a Bachelor Degree in Mechanical Engineering from the University of Strathclyde, United Kingdom.